FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Regulatory Review Period for Omegaven

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Fresenius Kabis Omegaven (f...

Changes Sought to FDAs IT Strategy

[ Price : $8.95]

Three trade groups raise concerns and make suggestions for the FDA Information Technology Strategy.

API CGMP Deviations at Ali Pharmaceutical

[ Price : $8.95]

FDA warns Omaha, NE-based Ali Pharmaceutical Manufacturing about significant CGMP deviations for active pharmaceutical ingredients...

Objectionable Conditions at BTS Research

[ Price : $8.95]

FDA warns San Diego, CA-based Samm Solutions about objectionable conditions in its role as the testing facility for two nonclinica...

X4 Pharma NDA Accepted for WHIM Syndrome

[ Price : $8.95]

FDA accepts for priority review an X4 Pharmaceuticals NDA for once-daily, oral mavorixafor to treat individuals aged 12 and older ...

FDA OKs Gene Therapy Trial for Heart Disease

[ Price : $8.95]

FDA approves a Tenaya Therapeutics IND for the company to begin a Phase 1b trial of TN-401, an adeno-associated virus serotype 9-b...

AdvaMed Points ONCD to Cyber Harmonization

[ Price : $8.95]

AdvaMed tells the National Cyber Director about domestic and international efforts involving FDA to harmonize medical device cyber...

Asensus Surgical Recalls Surgical System

[ Price : $8.95]

Asensus Surgical recalls its Senhance Surgical System due to the potential for the devices to malfunction.

17 Drugs Not Withdrawn Over Safety/Efficacy: FDA

[ Price : $8.95]

Federal Register notice: FDA determines that 17 listed drug products were not withdrawn from sale for safety or efficacy reasons.

Amgens Interchangeable Stelara Biosimilar Approved

[ Price : $8.95]

FDA approves an Amgen BLA for Wezlana (ustekinumab-auub), an interchangeable biosimilar to Janssens Stelara for multiple inflammat...